Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > About JDRF & Our Impact > Our research > Research projects > Stopping immune cells from launching an autoimmune attack
Connect Immune Research, our partnership with ten other autoimmune research organisations, awarded Lucy a grant for this project thanks to funding from The Lorna and Yuti Chernajovsky Biomedical Research Foundation.
Autoimmune conditions, like type 1 diabetes, happen when our immune system attacks our own cells instead of invading cells such as viruses. It’s common to have more than one autoimmune condition, and there are similarities between their underlying biology.
The similarities in autoimmune conditions are mostly early in disease development, when the immune system stops being properly controlled. This happens due to interactions between two types of immune cells called T cells and B cells – not to be confused with insulin-producing beta cells. When T cells start talking to B cells, it triggers proteins called autoantibodies to be produced, which target the beta cells.
The T cells that team up with B cells are called follicular helper T cells (Tfh). The Tfh start to change early on in several autoimmune conditions, including type 1. Targeting Tfh would be an innovative new way of intervening with the earliest stages of the immune attack to prevent multiple autoimmune conditions.
Lucy wants to find a way to deliver a toxic drug to only the Tfh cells to halt the autoimmune process, without affecting any other cells. She has developed a new chemical technique to create a drug to target the Tfh cells. Lucy and her team will test if the drug works by adding it to cells in plastic dishes and then to lab animals. Once she knows her method works, she will create a human version of the toxic drug and will begin testing it on human cells in a plastic dish.
In the first six months of her year-long project, Lucy developed a drug that is able to locate the Tfh cells and attach to them. Her initial experiments testing variations of the drug on mouse immune cells in a plastic dish allowed Lucy to fine tune it. She then attached a toxin (which damages the DNA of cells it enters) to her drug. This is a big achievement because it has never been done before with the particular type of drug and toxin that Lucy was using.
Next, Lucy will test the now-toxic drug in Tfh cells from mice in a petri dish. Her team has worked out how to edit their drug so that it works on human cells. This is crucial for translating their findings from mice to humans. They have also developed a test to study whether the drug works in human Tfh cells. Once the animal experiments are complete, Lucy will create the human version of the drug and test it on human cells in her lab.
Lucy’s project could ultimately form the basis of a new therapy for people in the early stages of autoimmune conditions including type 1 diabetes, rheumatoid arthritis, lupus, multiple sclerosis and many more. This means people who have been recently diagnosed with these conditions, or possibly even people who are at risk of developing them. By targeting the mechanisms that underlie disease development, rather than just the symptoms, this approach may offer a way to stop autoimmune diseases in their tracks.
Daniel Doherty’s research project aims to make islet transplants last longer and work better to benefit more people with type 1.
Lead researcher, Kourosh, says his study has the potential to transform our understanding of diabetes.
Dr Leslie Johnson will explore whether a collaborative care model that is effective for type 2 diabetes can be adapted for people with type 1.
Dr Chloe Rackham is investigating how supportive cells called mesenchymal stem cells may help protect people from developing type 1.